Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma
Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma
批准号:
8511195
负责人:
KENNETH W GROSS
金额:
$21.37万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-03-18 至 2015-02-28
关键词:
Animal ModelAnimalsCarcinogenesis MechanismCell Differentiation processCellsCessation of lifeClonal EvolutionClonal ExpansionClonalityCodeCollaborationsColorCpG IslandsDNA MethylationDevelopmentDiseaseDisease ProgressionDissectionDrug resistanceEndocrine Gland NeoplasmsEpigenetic ProcessEtiologyEventExhibitsExonsFDA approvedFosteringFutureGene ExpressionGene Expression ProfileGenesGeneticGenetic TranscriptionGenomeGenomicsGlucagonGoalsHumanHyperplasiaImageIndividualInvestigationIslet CellIslets of LangerhansLabelLettersLiteratureLiverLocationMalignant neoplasm of pancreasMetastatic Neoplasm to the LiverMetastatic toMethylationModelingMolecularMonitorMusMutationNatureNeoplasm MetastasisNeoplasmsNeuroendocrine TumorsNormal CellPancreasPancreatic Endocrine CarcinomaPathologyPathway interactionsPenetrancePhenotypePrimary NeoplasmProcessProtein Tyrosine KinaseRecurrenceReninRenin-Angiotensin SystemReporterReportingResistanceRoleRouteSDZ RADSiteStem cellsSymptomsSystemTherapeuticTimeLineTranscriptWorkcarcinogenesiscell typeclinically relevantepigenomeepigenomicsexomehistogenesishuman diseasein vivoinsulinomainterestisletloss of functionlymph nodesmTOR inhibitionmetastatic processmethylomemouse modelnext generation sequencingnovelpublic health relevanceresponsetranscriptomicstumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Neuroendocrine tumors of the pancreas are relatively rare but there remains considerable interest in these entities because of the complexity of the tumor spectrum and the uncertain histogenesis. Unfortunately, animal models that can faithfully replicate human disease and enable a more thorough investigation of the etiology of the disease process are few. We have created what appears to be a remarkably useful new animal model for pancreatic islet cell carcinoma as a result of cell-specifically deleting floxed Rb and p53 loc within the renin- expressing cell compartment of pancreas. The predominant neoplasia observed is an islet cell carcinoma, expressing glucagon, which arises with high penetrance and exhibits symptoms and profound metastatic spread to sites representative of the human disease, resulting in death by 5-6 months. In the human disease the primary metastatic sites are regional lymph nodes and liver, which is mimicked by our model. This model exhibits unique features which will allow us to foster better understanding of pancreatic islet cell development, the role the renin-angiotensin system therein, islet cell carcinogenesis, and the associated metastatic process, with the aim of ultimately identifying genetic signatures for these processes. We hypothesize that renin is transiently expressed in early glucagon lineage differentiation and that the loss of p53 and Rb predisposes these islet cells to frank carcinogenesis upon the occurrence of stochastic co-operating genetic and epigenetic abnormalities. Furthermore, we propose that additional or specific genomic insults are required for the cells to acquire a metastatic phenotype. Our hypothesis is supported by our preliminary findings that the renin expressing cells co-localize with the alpha islet cells expressing glucagon and that both primary and metastatic tumors, stochastically arising, continue to express glucagon. This is further supported by recent literature demonstrating that human pancreatic progenitor cells exhibit highly regulated expression of various components of the renin-angiotensin system throughout the progenitor cell differentiation to various islet cell types. The current proposal will use Next
Generation Sequencing of the exome, all transcripts, and of the methylome to identify co-operating mutations, gene expression changes and DNA methylation changes occurring within lineal descendants of the Rb-, p53-, renin-expressing cells of normal pancreatic islets that are associated with the stochastically arising primary tumors and corresponding liver metastases. Furthermore, the ability to use fluorescent reporters for lineage tracing of the cells contributing
to disease initiation and progression provides a unique opportunity to dissect the timeline of disease pathology. We further expect that the Confetti reporter will assist in the identification o clonal expansion of individual colored cells in the islet for each primary tumor, and facilitate correctly pairing the colored metastatic tumor with the same colored primary tumor. This will increase the power of the pairwise comparisons between primary and metastatic tumors and will ultimately allow for dissection of multiple molecular routes of metastatic spread.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma
-
批准号:8637941
-
项目类别:
-
资助金额:$17.01万
-
财政年份:2013
-
负责人:KENNETH W GROSS
-
依托单位:
Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma
-
批准号:8656515
-
项目类别:
-
资助金额:$2.03万
-
财政年份:2013
-
负责人:KENNETH W GROSS
-
依托单位:
Kidney Progenitor Cells in Disease
-
批准号:8268567
-
项目类别:
-
资助金额:$53.34万
-
财政年份:2012
-
负责人:KENNETH W GROSS
-
依托单位:
A novel murine model for metastatic islet cell pancreas cancer
-
批准号:8229338
-
项目类别:
-
资助金额:$21.96万
-
财政年份:2012
-
负责人:KENNETH W GROSS
-
依托单位:
A novel murine model for metastatic islet cell pancreas cancer
-
批准号:8435352
-
项目类别:
-
资助金额:$18.85万
-
财政年份:2012
-
负责人:KENNETH W GROSS
-
依托单位:
Gene Targeting & Transgenics
-
批准号:7714419
-
项目类别:
-
资助金额:$3.1万
-
财政年份:2008
-
负责人:KENNETH W GROSS
-
依托单位:
CORE--GENE TARGETING AND TRANSGENICS
-
批准号:7417859
-
项目类别:
-
资助金额:$5.29万
-
财政年份:2007
-
负责人:KENNETH W GROSS
-
依托单位:
Evaluation of Pericyte Molecular Markers in Clear Cell Kidney Cancer
-
批准号:7086088
-
项目类别:
-
资助金额:$16.68万
-
财政年份:2006
-
负责人:KENNETH W GROSS
-
依托单位:
Evaluation of Pericyte Molecular Markers in Clear Cell Kidney Cancer
-
批准号:7230150
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2006
-
负责人:KENNETH W GROSS
-
依托单位:
TRANSGENIC MUTANT WITH DOPAMINEGIC SYSTEM DYSFUNCTION
-
批准号:2249514
-
项目类别:
-
资助金额:$6.91万
-
财政年份:1993
-
负责人:KENNETH W GROSS
-
依托单位:
TRANSGENIC MUTANT WITH DOPAMINERGIC SYSTEM DYSFUNCTION
-
批准号:3430356
-
项目类别:
-
资助金额:$6.86万
-
财政年份:1993
-
负责人:KENNETH W GROSS
-
依托单位:
RENIN EXPRESSING CELL LINES FOR HYPERTENSION RESEARCH
-
批准号:6139157
-
项目类别:
-
资助金额:$27.8万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
Renin-expressing Cell Lines for Hypertension Research
-
批准号:7171555
-
项目类别:
-
资助金额:$43.3万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
RENIN EXPRESSING CELL LINES FOR HYPERTENSION RESEARCH
-
批准号:3367564
-
项目类别:
-
资助金额:$26.96万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
RENIN-EXPRESSING CELL LINES FOR HYPERTENSION RESEARCH
-
批准号:6261334
-
项目类别:
-
资助金额:$38.33万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
Renin-expressing Cell Lines for Hypertension Research
-
批准号:7033702
-
项目类别:
-
资助金额:$45.49万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
RENIN-EXPRESSING CELL LINES FOR HYPERTENSION RESEARCH
-
批准号:6638334
-
项目类别:
-
资助金额:$39.29万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
RENIN-EXPRESSING CELL LINES FOR HYPERTENSION RESEARCH
-
批准号:6537036
-
项目类别:
-
资助金额:$38.8万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
RENIN EXPRESSING CELL LINES FOR HYPERTENSION RESEARCH
-
批准号:2637990
-
项目类别:
-
资助金额:$26.2万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
RENIN EXPRESSING CELL LINES FOR HYPERTENSION RESEARCH
-
批准号:2028748
-
项目类别:
-
资助金额:$26.52万
-
财政年份:1992
-
负责人:KENNETH W GROSS
-
依托单位:
海外基金